论文部分内容阅读
目的:研究在肝细胞性肝癌中陷阱受体3(DcR3)的表达及其对微血管密度的影响。方法:收集40例肝癌患者肿瘤组织,及其癌旁组织,20例正常肝组织,用RT-PCR法检测组织中DcR3 mRNA的表达,流式细胞技术检测组织细胞凋亡,免疫组化S-P法检测肝组织中CD34的表达,得到微血管密度(MVD)值。结果:27例(67.5%)肝癌患者可以检测到DcR3mRNA,而癌旁肝组织及正常肝组织均未检测出DcR3mRNA。肝癌组平均凋亡率高于癌旁组和正常对照组(p<0.05)。肝癌患者DcR3表达与性别和年龄无关(p>0.05);在较大肿瘤、TNM分期高、有淋巴结转移、肿瘤侵犯门静脉和包膜不完整的情况下表达增高(p<0.05)。肝癌组织中血管内皮细胞均有不同程度的黄染,肝癌组MVD明显高于癌旁组和正常对照组(p<0.05)。27例DcR3阳性患者MVD值为142.65±45.63,明显高于13例阴性患者MVD值110.37±42.82(p<0.05)。结论:DcR3在肝癌组织中表达明显增高,可能促进肝癌发生与发展;DcR3可能在评估肝癌肿瘤分化、浸润深度、淋巴结转移,血管形成以及TNM分期中十分重要。
Objective: To investigate the expression of trap receptor 3 (DcR3) and its effect on the microvessel density in hepatocellular carcinoma. Methods: Tumor tissues of 40 HCC patients and their adjacent normal tissues were collected, and 20 normal liver tissues were collected. The expression of DcR3 mRNA was detected by RT-PCR. The apoptosis of the tissue was detected by flow cytometry. The expression of CD34 in liver tissue was detected and the microvessel density (MVD) value was obtained. Results: DcR3 mRNA was detected in 27 cases (67.5%) of hepatocellular carcinoma patients, while no DcR3 mRNA was detected in adjacent noncancerous liver tissues and normal liver tissues. The average rate of apoptosis in HCC group was higher than that in adjacent normal group and normal control group (p <0.05). The expression of DcR3 in hepatocellular carcinoma was not related to gender and age (p> 0.05). The expression of DcR3 was increased in large tumors with high TNM stage, lymph node metastasis, tumor invasion of portal vein and incomplete capsule (p <0.05). Vascular endothelial cells in HCC tissues had different degrees of yellow staining. The MVD in hepatocellular carcinoma was significantly higher than that in paracancer and normal controls (p <0.05). The MVD of 27 DcR3 positive patients was 142.65 ± 45.63, which was significantly higher than that of 13 negative patients (110.37 ± 42.82, p <0.05). Conclusion: The expression of DcR3 in hepatocellular carcinoma was significantly increased, which may promote the development and progression of hepatocellular carcinoma. DcR3 may play an important role in the assessment of tumor differentiation, depth of invasion, lymph node metastasis, angiogenesis and TNM staging.